Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Trevor Kitchin

Sports Medicine Westerville, OH Medical Doctor

NPI 1821431081 CMS profile 3448987

460 Polaris Pkwy Ste 100, Westerville, OH 43082

Open in the dashboard

General payments

$5,024

395 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Trevor Kitchin of Westerville, OH is reported in the CMS Open Payments database as having received $5,024 across 395 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $28 2
2023 General $658 43
2022 General $1,329 94
2021 General $714 53
2020 General $634 50
2019 General $1,661 153

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Trevor Kitchin
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Trevor Kitchin were reported at $0. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Trevor Kitchin Sports Medicine median Middle half National median
2019 $1,661 $119 $35–$362 $163
2020 $634 $77 $24–$275 $114
2021 $714 $104 $28–$340 $132
2022 $1,329 $94 $31–$272 $149
2023 $658 $91 $34–$271 $160
2024 $28 $126 $38–$294 $164
2025 $0 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Pfizer Inc. $660 66 payments
  2. AbbVie, Inc. $645 57 payments
  3. Novo Nordisk Inc $512 35 payments
  4. GlaxoSmithKline, LLC. $483 36 payments
  5. AstraZeneca Pharmaceuticals LP $435 26 payments
  6. Lilly USA, LLC $310 23 payments
  7. Janssen Pharmaceuticals, Inc $303 27 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $262 23 payments
  9. Merck Sharp & Dohme Corporation $235 23 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $148 10 payments
  11. Other $1,031 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,018 394 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2024
  1. Ozempic $429 27 payments
  2. TRELEGY ELLIPTA $374 27 payments
  3. FARXIGA $329 18 payments
  4. RYBELSUS $320 20 payments
  5. ELIQUIS $320 26 payments
  6. UBRELVY $317 27 payments
  7. XARELTO $268 25 payments
  8. PAXLOVID $225 13 payments
  9. STEGLATRO $187 18 payments
  10. VRAYLAR $178 16 payments
  11. Other $4,476 377 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

326

Median for Family Practice: 1,826

Drug cost

$925

Median for Family Practice: $120,094

Branded share of claims

5.8%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Naproxen Generic 59 $348
Prednisone Generic 151 $255
Meloxicam Generic 34 $112
Cyclobenzaprine Hcl Generic 39 $110
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 19 $74
Tramadol Hcl Generic 24 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$84,920

Of which drugs: $14,334

Medicare patients

391

Average age 74

Services billed

2,672

232 women, 159 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Depression 32%
Chronic kidney disease 27%
Diabetes 26%
Ischemic heart disease 23%
Osteoporosis 19%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 20 90 $8,306
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 111 696 $501

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $14
$14 — —
UBRELVY
  • AbbVie, Inc. $7
$7 — —
QULIPTA
  • AbbVie, Inc. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

395 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record